Prat, Aleix http://orcid.org/0000-0003-2377-540X
Brasó-Maristany, Fara http://orcid.org/0000-0001-5440-9643
Martínez-Sáez, Olga http://orcid.org/0000-0001-8686-0236
Sanfeliu, Esther
Xia, Youli
Bellet, Meritxell http://orcid.org/0000-0001-8859-8307
Galván, Patricia
Martínez, Débora
Pascual, Tomás http://orcid.org/0000-0001-8431-3183
Marín-Aguilera, Mercedes
Rodríguez, Anna
Chic, Nuria
Adamo, Barbara
Paré, Laia
Vidal, Maria http://orcid.org/0000-0003-1992-5727
Margelí, Mireia
Ballana, Ester
Gómez-Rey, Marina
Oliveira, Mafalda http://orcid.org/0000-0001-9152-8799
Felip, Eudald
Matito, Judit
Sánchez-Bayona, Rodrigo
Suñol, Anna
Saura, Cristina http://orcid.org/0000-0001-8296-5065
Ciruelos, Eva
Tolosa, Pablo http://orcid.org/0000-0002-3747-4766
Muñoz, Montserrat
González-Farré, Blanca
Villagrasa, Patricia
Parker, Joel S.
Perou, Charles M.
Vivancos, Ana
Funding for this research was provided by:
Breast Cancer Now (2018NOVPCC1294)
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI19/01846)
EC | Horizon 2020 Framework Programme (847912)
Article History
Received: 2 September 2022
Accepted: 14 February 2023
First Online: 1 March 2023
Competing interests
: Potential conflicts of interest are the following: A.P. reports advisory and consulting fees from Roche, Pfizer, Novartis, Amgen, BMS, Puma, Oncolytics Biotech, MSD, Guardan Health, Peptomyc and Lilly, lecture fees from Roche, Pfizer, Novartis, Amgen, BMS, Nanostring Technologies and Daiichi Sankyo, institutional financial interests from Boehringer, Novartis, Roche, Nanostring, Sysmex Europa GmbH, Medica Scientia inno. Research, SL, Celgene, Astellas and Pfizer; stockholder and consultant of Reveal Genomics, SL; a patent PCT/EP2016/080056 and the DNADX patent filed (EP22382387.3). F.B-M. has the DNADX patent filed (EP22382387.3). P.V. has the DNADX patent filed (EP22382387.3). C.M.P is an equity stockholder and consultant of BioClassifier LLC, and for Reveal Genomics. C.M.P is also listed as an inventor on patent applications for the Breast PAM50 assay, and a patent application on DNA-based predictors of breast tumor phenotypes. J.S.P is an equity stockholder and consultant for Reveal Genomics and is also listed as an inventor on patent applications for the Breast PAM50 assay, and a patent application on DNA-based predictors of breast tumor phenotypes. A.V. has the DNADX patent filed (EP22382387.3). The remaining authors declare no competing interests.